IHL 0.00% 4.1¢ incannex healthcare limited

The biggest obstacle we face here with IHL-675A, apart from...

  1. 10,220 Posts.
    lightbulb Created with Sketch. 2797
    The biggest obstacle we face here with IHL-675A, apart from passing the Stage 2 animal trials which I'm quietly confident about, is to see whether we observe the same response in humans. If we get the green light on it being safe and efficacious in humans, that'll be my cue to start getting that resignation letter togetherbiggrin.png
 
watchlist Created with Sketch. Add IHL (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.